NL-OMON54142招募中不适用
ong-term integrity of hematopoiesis in pediatric stem cell transplantation survivors - Long-term hematopoiesis in transplantation survivors (Long-term HIT)
Prinses Máxima Centrum voor Kinderoncologie0 个研究点目标入组 375 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 375
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 64（—）
入选标准
- •Underwent allogeneic HSCT at age <40 yrs
- •A minimum survival of 5 years after HSCT.
排除标准
- •Failure of the HSCT recipient, donor and/or their legal representatives to
- •understand the patient information and informed consent form (either due to
- •intellectual disability or to language problems).
- •Recipients of a *NiCord* HSCT. NiCord is a clinical trial on the safety and
- •efficacy of transplantation of ex vivo expanded cord blood HSCs. As outcome
- •measures of our study overlap with the outcome of this trial, NiCord recipients
- •will be excluded.
研究者
相似试验
尚未招募
不适用
ong-term hematopoiesis in transplantation survivorsAllogeneic Hematopoietic Stem Cell TransplantationNL-OMON20624Prinses Máxima Center for Pediatric Oncology150
已完成
不适用
Impact of immature haematopoetic cells on clinical risk stratification of patients with coagulation inhibitor therapycardiolgical, angiological, heart and vascular surgical interventionsDRKS00028143niversitäts-Herzzentrum Freiburg- Bad Krozingen, Campus Bad Krozingen17,835
招募中
不适用
Bonehealth in children and adolescents with hematologic/oncologic diseasescomplete spectrum of paediatric oncologic diseases.chronic haematological diseases (sickle cell, thalassemia)C00-C97D55-D59Malignant neoplasmsHaemolytic anaemiasDRKS00003636Abteilung für Hämatologie und OnkologieKinderklinik IIIUniversitätsklinikum Essen1,000
招募中
不适用
A prospective study of pediatric hereditary hematological disordersPediatric hereditary hematological disordersJPRN-UMIN000037774agoya university1,000
招募中
不适用
Immune cell profiles in the blood in children, adolescents and adults with tuberous sclerosis complex disease and their correlation with organ manifestations and treatment response to immunotherapy with mTOR inhibitorsQ85.1G40Tuberous sclerosisEpilepsyDRKS00022991niversitätsklinikum Münster90